Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab

Affiliations

• ¹ Department of Haemato-Oncology, John Vane Cancer Centre, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, UK.
• ² Department of Biostatistics, Roche Products Limited, Welwyn Garden City, UK.
• ³ Department of Statistical Programming and Analysis, Roche Products Limited, Welwyn Garden City, UK.
• ⁴ German CLL Study Group, Center of Integrated Oncology Cologne-Bonn, Department of Internal Medicine, University Hospital Cologne, Cologne, Germany.
• ⁵ Pharma Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
• ⁶ Pharma Development Clinical Science, Roche Products Limited, Welwyn Garden City, UK.
• ⁷ University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
• ⁸ Roche Pharmaceutical Research and Early Development (pRED), Pharmaceutical Sciences (PS), Roche Innovation Centre Basel, Basel, Switzerland.
• ⁹ Department of Internal Medicine III, Ulm University, Ulm, Germany.
• ¹⁰ Department I of Internal Medicine Centre of Integrated Oncology Köln Bonn and Cluster of Excellence on Cellular Stress Responses in Aging (CECAD) University of Cologne, Cologne, Germany.